Future Fund LLC Buys 4,363 Shares of Edwards Lifesciences Co. (NYSE:EW)

Future Fund LLC raised its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 37.8% during the 3rd quarter, Holdings Channel.com reports. The fund owned 15,898 shares of the medical research company’s stock after purchasing an additional 4,363 shares during the quarter. Edwards Lifesciences makes up approximately 3.2% of Future Fund LLC’s portfolio, making the stock its 16th largest holding. Future Fund LLC’s holdings in Edwards Lifesciences were worth $1,074,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of EW. Avantax Advisory Services Inc. lifted its stake in shares of Edwards Lifesciences by 4.1% in the 1st quarter. Avantax Advisory Services Inc. now owns 6,887 shares of the medical research company’s stock worth $658,000 after purchasing an additional 272 shares during the period. Cozad Asset Management Inc. purchased a new stake in Edwards Lifesciences in the 1st quarter worth approximately $250,000. TD Asset Management Inc increased its holdings in Edwards Lifesciences by 10.6% in the 1st quarter. TD Asset Management Inc now owns 1,463,308 shares of the medical research company’s stock worth $139,834,000 after acquiring an additional 139,697 shares in the last quarter. State Board of Administration of Florida Retirement System increased its holdings in Edwards Lifesciences by 2.8% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 689,009 shares of the medical research company’s stock worth $65,842,000 after acquiring an additional 18,998 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in Edwards Lifesciences by 18.5% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 708,917 shares of the medical research company’s stock worth $67,744,000 after acquiring an additional 110,591 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the transaction, the insider now directly owns 198,526 shares in the company, valued at approximately $13,084,848.66. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the transaction, the insider now directly owns 198,526 shares in the company, valued at approximately $13,084,848.66. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction dated Wednesday, September 11th. The shares were sold at an average price of $66.77, for a total transaction of $333,850.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,133,916.72. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 36,250 shares of company stock valued at $2,416,588 over the last three months. 1.27% of the stock is owned by company insiders.

Edwards Lifesciences Stock Down 1.3 %

NYSE:EW opened at $65.81 on Wednesday. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The company has a 50-day moving average of $67.53 and a 200 day moving average of $76.65. The firm has a market cap of $38.81 billion, a PE ratio of 9.50, a price-to-earnings-growth ratio of 3.75 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The company had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same period in the prior year, the firm earned $0.59 earnings per share. The firm’s revenue for the quarter was up 8.9% compared to the same quarter last year. As a group, research analysts anticipate that Edwards Lifesciences Co. will post 2.57 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on EW. Morgan Stanley reissued an “equal weight” rating and issued a $70.00 target price on shares of Edwards Lifesciences in a report on Friday, October 11th. Stifel Nicolaus cut their target price on shares of Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating for the company in a report on Thursday, July 25th. Jefferies Financial Group lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and cut their target price for the company from $85.00 to $70.00 in a report on Wednesday, September 18th. StockNews.com lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Thursday, July 25th. Finally, The Goldman Sachs Group cut their target price on shares of Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating for the company in a report on Friday, July 26th. Seventeen analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $75.67.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.